RZLT

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc. (RZLT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) B- (3.1) C (2.4) C+ (2.6) A+ (5.0) B- (3.1)
2026-11-07 C+ (2.5) B- (3.1) C- (1.9) B- (3.0) A+ (5.0) B- (3.1)
2026-10-31 C+ (2.5) B- (2.9) C+ (2.5) C+ (2.6) A+ (5.0) B- (3.1)
2026-10-24 C+ (2.5) B- (2.9) C+ (2.5) C (2.4) A+ (5.0) B- (3.0)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe